BR112017017553A2 - ?anticorpos direcionados contra um antígeno o baseado em galactano de k. pneumoniae, método de produção, preparação farmacêutica ou diagnóstica, método de diagnóstico, método de identificação, ácido nucleico isolado, célula hospedeira e invólucro de expressão? - Google Patents

?anticorpos direcionados contra um antígeno o baseado em galactano de k. pneumoniae, método de produção, preparação farmacêutica ou diagnóstica, método de diagnóstico, método de identificação, ácido nucleico isolado, célula hospedeira e invólucro de expressão?

Info

Publication number
BR112017017553A2
BR112017017553A2 BR112017017553A BR112017017553A BR112017017553A2 BR 112017017553 A2 BR112017017553 A2 BR 112017017553A2 BR 112017017553 A BR112017017553 A BR 112017017553A BR 112017017553 A BR112017017553 A BR 112017017553A BR 112017017553 A2 BR112017017553 A2 BR 112017017553A2
Authority
BR
Brazil
Prior art keywords
diagnostic
galactan
pharmaceutical
pneumoniae
nucleic acid
Prior art date
Application number
BR112017017553A
Other languages
English (en)
Portuguese (pt)
Inventor
Luis Guachalla
Jolanta Katarzyna Lukasiewicz
Eszter Nagy
Gábor Nagy
Valeria Szijárto
Zehra Visram
Original Assignee
Arsanis Biosciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arsanis Biosciences Gmbh filed Critical Arsanis Biosciences Gmbh
Publication of BR112017017553A2 publication Critical patent/BR112017017553A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/26—Klebsiella (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112017017553A 2015-02-17 2015-11-03 ?anticorpos direcionados contra um antígeno o baseado em galactano de k. pneumoniae, método de produção, preparação farmacêutica ou diagnóstica, método de diagnóstico, método de identificação, ácido nucleico isolado, célula hospedeira e invólucro de expressão? BR112017017553A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15155448 2015-02-17
PCT/EP2015/075583 WO2016131503A1 (en) 2015-02-17 2015-11-03 Antibodies targeting a galactan-based o-antigen of k. pneumoniae

Publications (1)

Publication Number Publication Date
BR112017017553A2 true BR112017017553A2 (pt) 2018-05-08

Family

ID=52469764

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017017553A BR112017017553A2 (pt) 2015-02-17 2015-11-03 ?anticorpos direcionados contra um antígeno o baseado em galactano de k. pneumoniae, método de produção, preparação farmacêutica ou diagnóstica, método de diagnóstico, método de identificação, ácido nucleico isolado, célula hospedeira e invólucro de expressão?

Country Status (12)

Country Link
US (2) US11466074B2 (https=)
EP (1) EP3259287A1 (https=)
JP (2) JP6987638B2 (https=)
KR (1) KR20170122726A (https=)
CN (1) CN107371365B (https=)
AU (1) AU2015383632B2 (https=)
BR (1) BR112017017553A2 (https=)
CA (1) CA2973134A1 (https=)
IL (1) IL253920B2 (https=)
MX (1) MX2017009955A (https=)
RU (2) RU2021131224A (https=)
WO (1) WO2016131503A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017017553A2 (pt) * 2015-02-17 2018-05-08 Arsanis Biosciences Gmbh ?anticorpos direcionados contra um antígeno o baseado em galactano de k. pneumoniae, método de produção, preparação farmacêutica ou diagnóstica, método de diagnóstico, método de identificação, ácido nucleico isolado, célula hospedeira e invólucro de expressão?
KR20190077306A (ko) 2016-08-05 2019-07-03 메디뮨 엘엘씨 항-o2 항체 및 이의 용도
SG11201903063UA (en) * 2016-10-19 2019-05-30 Medimmune Llc Anti-o1 antibodies and uses thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN120775040A (zh) * 2021-08-25 2025-10-14 北京三诺佳邑生物技术有限责任公司 特异性识别肺炎克雷伯菌o1抗原的抗体及其应用
EP4445911A4 (en) 2021-12-06 2025-10-22 Beijing Solobio Genetechnology Co Ltd BISPECIFIC ANTIBODY THAT BINDS SPECIFICALLY TO KLEBSIELLA PNEUMONIAE O1 AND O2 ANTIGENS AND COMPOSITION
CN118620072A (zh) * 2023-12-27 2024-09-10 上海博钒生物科技有限公司 一种肺炎克雷伯菌多糖单克隆抗体、其杂交瘤细胞株及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US20050112141A1 (en) * 2000-08-30 2005-05-26 Terman David S. Compositions and methods for treatment of neoplastic disease
EA013564B1 (ru) * 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
BR112017017553A2 (pt) * 2015-02-17 2018-05-08 Arsanis Biosciences Gmbh ?anticorpos direcionados contra um antígeno o baseado em galactano de k. pneumoniae, método de produção, preparação farmacêutica ou diagnóstica, método de diagnóstico, método de identificação, ácido nucleico isolado, célula hospedeira e invólucro de expressão?

Also Published As

Publication number Publication date
KR20170122726A (ko) 2017-11-06
JP2018508208A (ja) 2018-03-29
US20180066041A1 (en) 2018-03-08
CN107371365A (zh) 2017-11-21
CA2973134A1 (en) 2016-08-25
MX2017009955A (es) 2017-10-19
AU2015383632A1 (en) 2017-07-27
CN107371365B (zh) 2022-01-11
RU2021131224A (ru) 2021-11-03
IL253920B (en) 2022-10-01
IL253920B2 (en) 2023-02-01
US20230220055A1 (en) 2023-07-13
EP3259287A1 (en) 2017-12-27
JP6987638B2 (ja) 2022-01-05
AU2015383632B2 (en) 2021-10-21
RU2759950C2 (ru) 2021-11-19
WO2016131503A1 (en) 2016-08-25
IL253920A0 (en) 2017-10-31
US11466074B2 (en) 2022-10-11
RU2017132168A3 (https=) 2019-06-11
RU2017132168A (ru) 2019-03-18
JP2022058341A (ja) 2022-04-12

Similar Documents

Publication Publication Date Title
BR112017017553A2 (pt) ?anticorpos direcionados contra um antígeno o baseado em galactano de k. pneumoniae, método de produção, preparação farmacêutica ou diagnóstica, método de diagnóstico, método de identificação, ácido nucleico isolado, célula hospedeira e invólucro de expressão?
BR112019008634A2 (pt) anticorpos anti-pd-l1 e variantes
CO2020003882A2 (es) Anticuerpo multiespecifico
BR112013008822A2 (pt) novas fucosiltransferases e suas aplicações
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
IL286394A (en) Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
BR112016017155A2 (pt) Sistema e dispositivo para geração com alto rendimento de gotículas combinatoriais e métodos de uso
BR112019002579A2 (pt) anticorpos biespecíficos fab monovalentes, assimétricos e tandem
BR112019011582A2 (pt) anticorpos e métodos de utilização dos mesmos
PE20151613A1 (es) Construcciones de anticuerpos para cdh19 y cd3
AU2015347015A8 (en) Antibody drug conjugates
IL286467A (en) Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
BR112016026956A2 (pt) método para a produção enzimática de d-eritrose e acetilfosfato".
BR112017010923A2 (pt) misturas de milho que incluem milho com alto teor de óleo e métodos de fabricar um ou mais produtos bioquímicos usando milho com alto teor de óleo ou misturas de milho que incluem milho com alto teor de óleo
MX2017003989A (es) Alfa-glucosidasa acida altamente potente con carbohidratos mejorados.
MX390764B (es) Ensayos dispersables en agua
MX2018008110A (es) Metodo para desacetilacion de biopolimeros.
BR112014018113A8 (pt) método implementado por computador para determinar uma pluralidade de propriedades elásticas para uma formação geológica anisotrópica heterogênea, meio não transitório legível por computador codificado com instruções, e sistema para determinar uma pluralidade de propriedades elásticas para uma formação geológica anisotrópica heterogênea
BR112014017203A2 (pt) método, sistema de computador e meio não transitório de leitura por computador
GB2540702A (en) Nucleic acid processing of a nucleic acid fragment with a triazole linkage
MX394233B (es) Anticuerpo específico contra e. coli mdr.
BR112017013576A2 (pt) produção melhorada de lipídios de núcleo em leveduras oleaginosas
BR112015011872A2 (pt) sistema, método implementado por processador e artigo
BR112017007413A2 (pt) método para gerar um perfil de aderência de cimento e sistema para avaliar a aderência de cimento em um poço de exploração
BR112017023378A2 (pt) moléculas de direcionamento do sistema de secreção do tipo iii

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: ARSANIS BIOSCIENCES GMBH (AT)

Free format text: A FIM DE ATENDER A(S) ALTERACAO(OES) DE NOME REQUERIDA(S) ATRAVES DA PETICAO NO 870190120485 DE 20/11/2019, E NECESSARIO:1. APRESENTAR TRADUCAO JURAMENTADA DO DOCUMENTO QUE COMPROVA A ALTERACAO SOLICITADA;2. QUE O DOCUMENTO QUE COMPROVA A ALTERACAO ESTEJA COM A DEVIDA LEGALIZACAO CONSULAR OUACOMPANHANDO DA APOSTILA DE HAIA;3. APRESENTAR GRU REFERENTE AO CUMPRIMENTO DA PRESENTE EXIGENCIA.

B25A Requested transfer of rights approved

Owner name: X4 PHARMACEUTICALS GMBH (AT)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: X4 PHARMACEUTICALS GMBH (AT)

Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2566 DE 10/03/2020 POR TER SIDO INDEVIDA.

B25D Requested change of name of applicant approved

Owner name: X4 PHARMACEUTICALS GMBH (AT)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.